Also, the ASX 300 buys were done in a fixed deal, the sale could be done in a similar fashion. If not it will lower the price on the ASX but as we already know the U.S. market doesn't GAF where the ASX trades.
R/S would not keep them on the ASX 300, the market cap determines their spot. And pennies are the norm over there.
No placebos in the trial? All the placebos are in the extension trial... No, I know what you mean. The alternative to what I said is worse. Let's assume I'm wrong and the market is not skeptical. The trial is practically done so $1.65 has extension expectations baked in.
CHG, I agree. Prana could be managed much better. There is evidence of poor management littered all over the company history and we are lacking checks and balances needed to protect shareholders. This isn't something new, it has always been this way. Kempler provided the seed money for what is Prana and despite having no relative experience or knack for the role he has managed to stay CEO while residing as chairman over a friendly BOD that is uninvolved. This is a conflict of interest. Shoulson is an exception, and is basically carrying this company now.
Disadvantaged companies like Prana are strong candidates for patent extensions. Like everything else in life there are no guarantees. In the countries that matter Prana's protection will run out between 2023-2028. I believe most extensions add 4 years. They can't put AD on the back burner.
Huge and costly for sure. I'm surprised more shareholders don't want Kempler's head. There were months where Prana could have sold 50% of the ATM into the market at a great price. $6-7 would have been fine too. It would have given an indication to the market that the company did not know what the results would be. As it was with the Lawler interview, the HD trial results, Credit Suisse initiative, and the general hype, Prana played the greatest role in it by not exercising a single ATM share prior to the trial, emitting a false sense of confidence that fed the market.
While they are a great group it is a team of people whose time is divided with other work, research, teaching etc. I would like to see at least one full time member who has strong U.S. pharmaceutical industry experience and connections in a top management role, or even as CEO with Kempler remaining Chairman of the Board.
Call, you turned into a douchebag the instant you went to puts. The OP is planning to hold for whatever length of time is required to recoup his money. This wasn't short term advice. Vale is not doomed for life, and I recall he bought in the low 11's so his current loss is menial. I've seen many people time their buy poorly only to wait a length of time and sell the moment they are back to even, missing out on what is a turn around.
I voted against everything and everyone except Shoulson. Join me fellow peasants, express your dissatisfaction for Lord Kempler and the friends and family BOD that oversee him.
Glad to see that because I wasn't thrilled with Revelins. On the other hand Prana has now lost a body in the U.S. as well as further integrated the CFO Solutions employees into the company.
This is just a standard thing and a continuation of the F3 filed in July. It wasn't worth it for Pran to file an extension for the remaining shares in the shelf. I believe this is just part of the process for authorizing a new batch of shares to have available if they wish to raise capital at some point in the future.